SCHEMBL1542465

SCHEMBL1542465

COC(=O)c1cc(NS(C)(=O)=O)ccc1/C=C/c1cc(-c2ccc[nH]c2=O)cc(C(C)(C)C)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.59
ABL1 P00519 2/20 0.38
CHEK1 O14757 1/20 0.38
AURKA O14965 1/20 0.38
DAPK3 O43293 1/20 0.38
JAK2 O60674 1/20 0.38
NTRK1 P04629 1/20 0.38
FYN P06241 1/20 0.38
CSF1R P07333 1/20 0.38
RET P07949 1/20 0.38
IGF1R P08069 1/20 0.38
MET P08581 1/20 0.38
PDGFRB P09619 1/20 0.38
PIM1 P11309 1/20 0.38
FGFR1 P11362 1/20 0.38
PRKACA P17612 1/20 0.38
LTK P29376 1/20 0.38
GRK5 P34947 1/20 0.38
KDR P35968 1/20 0.38
MAP2K2 P36507 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2129952 1.00 CYP3A4 (0.59) CYP3A4ABL1CHEK1AURKADAPK3
SCHEMBL2127515 0.91 CYP3A4 (0.56) CYP3A4ABL1TRPV1PDPK1HPGD
SCHEMBL1542857 0.91 CYP3A4 (0.56) CYP3A4ABL1TRPV1PDPK1HPGD
SCHEMBL1764952 0.86 CYP3A4 (0.76) CYP3A4ABL1CHEK1AURKADAPK3
SCHEMBL1542952 0.86 CYP3A4 (0.76) CYP3A4ABL1CHEK1AURKADAPK3
SCHEMBL1764453 0.85 CYP3A4 (0.52) CYP3A4ABL1TRPV1PDPK1HPGD
SCHEMBL1350896 0.84 CYP3A4 (0.51) CYP3A4ABL1CHEK1AURKADAPK3
SCHEMBL1350894 0.84 CYP3A4 (0.51) CYP3A4ABL1CHEK1AURKADAPK3
SCHEMBL1543239 0.83 CYP3A4 (0.68) CYP3A4TRPV1PDPK1BRD4IKBKB
SCHEMBL1543237 0.83 CYP3A4 (0.68) CYP3A4TRPV1PDPK1BRD4IKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885ABL1 584/4885CHEK1 1463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.